OSUR News Alert Orasure Technologies (OSUR) 9.49 12/13/2014

New Post Public Reply Private Reply Replies (0) Message Board

Dec 13, 2014 at 6:27 AM

Orasure Technologies (OSUR) 9.49 $OSUR

Will Medtronic's Endurant AAA Stent Graft Last Long? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Dec 12, 1:40PM CST
Medtronic's (MDT) Endurant AAA stent graft system ??? a global leader in the coronary & structural heart device category ??? is compatible with a broad range of aortic anatomies.
ICUI: 80.95 (-1.04), MDT: 72.52 (-1.25), ABAX: 57.20 (+0.61), OSUR: 9.49 (-0.25)

St. Jude Medical's Quadra Allure Pacemaker Gets CE Mark - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Dec 12, 11:30AM CST
The Quadra Allure MP CRT-P expands St. Jude Medical Inc.'s (STJ) heart failure portfolio which includes the CardioMEMS HF Monitoring System, implantable cardioverter defibrillators, quadripolar and multi-point pacing systems.
ICUI: 80.95 (-1.04), ABAX: 57.20 (+0.61), STJ: 66.33 (-0.68), OSUR: 9.49 (-0.25)

Agios Pharmaceuticals (AGIO) Looks Good: Stock Up 6.9% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Dec 12, 8:25AM CST
Agios Pharmaceuticals (AGIO) was a big mover last session, with shares rising nearly 7% on the day.
ICUI: 80.95 (-1.04), ABAX: 57.20 (+0.61), AGIO: 119.56 (+0.36), OSUR: 9.49 (-0.25)

TG Therapeutics, Inc. (TGTX) in Focus: Stock Soars 21.2% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Dec 12, 8:21AM CST
TG Therapeutics, Inc. (TGTX) was a big mover last session, as the company saw its shares rise by over 21% on the day.
ICUI: 80.95 (-1.04), ABAX: 57.20 (+0.61), TGTX: 18.25 (+0.74), OSUR: 9.49 (-0.25)

Baxter Files Form 10 with SEC, Advances Baxalta Spin-off - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Dec 11, 11:40AM CST
In March this year, Baxter International Inc. (BAX) had announced its intention to separate its biopharmaceuticals and medical device segments into two independent companies - Baxter International Inc. and Baxalta Incorporated.
ICUI: 80.95 (-1.04), ABAX: 57.20 (+0.61), BAX: 71.77 (-1.34), OSUR: 9.49 (-0.25)

Alere's HIV Combo Test Gets CLIA Waiver from the FDA - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Dec 11, 11:20AM CST
Shares of Alere Inc. (ALR) rose 1.1% in the trading session after the news on Tuesday but pulled back to close the day lower at $37.86.
ICUI: 80.95 (-1.04), ABAX: 57.20 (+0.61), ALR: 36.32 (-0.67), OSUR: 9.49 (-0.25)

Integral Molecular identifies potent inhibitory antibodies against Chikungunya virus
Business Wire - Wed Dec 10, 1:00PM CST
Integral Molecular, a leader in membrane protein antibody discovery, in conjunction with Blood Systems Research Institute (BSRI), has identified potent inhibitory human antibodies against the debilitating mosquito-borne Chikungunya virus (CHIKV). The lead candidate, IM-CKV063, is one of the most potent antibodies against CHIKV isolated to date, and protects animals from CHIKV-induced lethality and arthritis. This work, described by Fong et al., appears in the current issue of the Journal of Virology (December 2014).
OSUR: 9.49 (-0.25)

OraSure Technologies Has Returned 22.3% Since SmarTrend Recommendation (OSUR)
Comtex SmarTrend(R) - Wed Dec 10, 9:53AM CST
SmarTrend identified an Uptrend for OraSure Technologies (NASDAQ:OSUR) on October 13th, 2014 at $8.09. In approximately 2 months, OraSure Technologies has returned 22.33% as of today's recent price of $9.89.
OSUR: 9.49 (-0.25)

Unveiled House Spending Bill Bullish For Ebola Stocks
Matthew Finston - at Seeking Alpha - Wed Dec 10, 8:46AM CST

NVAX: 5.76 (-0.17), NLNK: 35.69 (+0.27), OSUR: 9.49 (-0.25)

After Hour Gainers / Losers
Seeking Alpha - at Seeking Alpha - Mon Dec 08, 4:41PM CST

BTE: 13.41 (+0.12), PBY: 8.80 (+0.22), ETE: 51.89 (+0.15), AGI: 7.04 (-0.20), TMUS: 25.31 (-0.33), SYRG: 10.07 (+0.58), FET: 17.82 (-0.81), ARO: 2.31 (+0.09), HRB: 31.96 (+0.20), OSUR: 9.49 (-0.25)

Is Merge Healthcare (MRGE) a Buy after Strong Q3 Results? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Dec 08, 1:40PM CST
On Dec 5, 2014, we issued an updated research report on Merge Healthcare Incorporated (MRGE).
ICUI: 80.95 (-1.04), AMED: 26.81 (-0.32), MRGE: 3.42 (-0.06), OSUR: 9.49 (-0.25)

Medtronic-Covidien Deal Nears Finish Line, Approvals Flow In - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Dec 08, 1:30PM CST
Medtronic, Inc. (MDT) recently announced that it has received the nod from the Chinese Ministry of Commerce as well as the South Korean Fair Trade Commission.
ICUI: 80.95 (-1.04), MDT: 72.52 (-1.25), COV: 100.49 (-1.36), OSUR: 9.49 (-0.25)

Baxter: Strong Sell on Prevailing Headwinds, Estimate Revision - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Dec 05, 12:50PM CST
On Dec 5, 2014, Zacks Investment Research downgraded Baxter International Inc. (BAX) to a Zacks Rank #5 (Strong Sell).
ICUI: 80.95 (-1.04), GWPH: 72.41 (+1.18), BAX: 71.77 (-1.34), OSUR: 9.49 (-0.25)

Meridian Bioscience: A Strong Sell on Dismal Q4, Competition - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Dec 04, 12:40PM CST
On Dec 2, 2014, Zacks Investment Research downgraded diagnostic test-kit maker Meridian Bioscience Inc. (VIVO) to a Zacks Rank #5 (Strong Sell).
ICUI: 80.95 (-1.04), INSY: 41.00 (+1.82), VIVO: 16.36 (-0.35), OSUR: 9.49 (-0.25)

Strength Seen in Cardica (CRDC): Stock Moves 8.7% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Dec 04, 8:25AM CST
Cardica (CRDC) was a big mover last session, with shares rising nearly 9% on the day.
ICUI: 80.95 (-1.04), ABAX: 57.20 (+0.61), CRDC: 0.62 (-0.02), OSUR: 9.49 (-0.25)

Shares of OSUR Up 17.0% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Wed Dec 03, 9:25AM CST
SmarTrend identified an Uptrend for OraSure Technologies (NASDAQ:OSUR) on October 13th, 2014 at $8.09. In approximately 2 months, OraSure Technologies has returned 17.01% as of today's recent price of $9.46.
OSUR: 9.49 (-0.25)

Baxter Files BLA for BAX 855 in Hemophilia A Treatment - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Dec 02, 11:40AM CST
Baxter International Inc (BAX) recently filed a biologics license application (BLA) with the U.S. Food and Drug Administration (FDA) for the approval of BAX 855.
ICUI: 80.95 (-1.04), BAX: 71.77 (-1.34), NKTR: 15.31 (-0.29), OSUR: 9.49 (-0.25)

OraSure Technologies Announces 2015 Annual Meeting Date
GlobeNewswire - Tue Dec 02, 5:45AM CST
OraSure Technologies, Inc. (Nasdaq:OSUR) today announced that its 2015 Annual Meeting of Stockholders is scheduled to be held on Monday, May 11, 2015. Further details regarding the meeting will be provided at a later date.
OSUR: 9.49 (-0.25)

Medtronic-Covidien Deal Wins European Commission Go-Ahead - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Dec 01, 1:40PM CST
The European Commission has also cleared Medtronic Inc.'s (MDT) proposed $42.9 billion acquisition of Covidien plc (COV).
ICUI: 80.95 (-1.04), MDT: 72.52 (-1.25), COV: 100.49 (-1.36), OSUR: 9.49 (-0.25)

FTC OKs Medtronic-Covidien Deal on Asset Sale Clauses - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Nov 27, 12:40PM CST
The U.S. FTC has finally approved Medtronic's proposed $42.9 billion acquisition of Covidien, subject to certain conditions.
ICUI: 80.95 (-1.04), MDT: 72.52 (-1.25), COV: 100.49 (-1.36), OSUR: 9.49 (-0.25)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Novo's Research Unlocks New Insights into Food Noise

Unpacking the Science Behind Food Noise When folks think about losing weight, most picture shedding pounds and fitting into those elusive smaller jeans. But get this—there’s a curveball called ‘food noise’ that’s making waves in obesity treatment. Novo Nordisk’s semaglutide injections are shaking things up, cutting down on those persistent thoughts about food....

Novo's CagriSema Trial Shows Promising Obesity Results

Novo's Latest Weight Loss Gamble Well, look what we have here. Novo Nordisk is shaking up the obesity treatment scene with some bold numbers from their REDEFINE 9 trial. The investigational CagriSema combo of amylin analog and GLP-1 receptor agonist has churned out an eyeball-popping near 21% weight loss. For context, we're staring down the barrel of numbers far meatier...

HONGQI's EHS4 Launch in Europe: Bridging East and West

Revving Up a New Chapter: HONGQI in Venice There's a new player in the European automotive scene, and it's rolling in with more style than a Venetian gondola. HONGQI, a name that's been turning gears in China since '58, is packing its suitcases full of Eastern elegance and landing straight in Venice with the all-electric EHS4. On November 16, the brand is set to unveil...

CARsgen's CAR-T Breakthrough on China's Insurance List

A Game Changer for CAR-T Therapies There's a breeze of optimism blowing from Shanghai these days—a rare sensation in this market of endless skirmishes. CARsgen Therapeutics Holdings Limited, a company entrenched in the development of cutting-edge CAR T-cell therapies, just notched a victory. They've announced that their CAR T-cell therapy product, satricabtagene...

EFICYENT Ventures to Connect at Singapore FinTech Fest

Why the Singapore FinTech Festival Matters The world's hardly a stranger to hype, but the Singapore FinTech Festival carries some real weight. From November 18 to 20, 2026, this gig isn't just industry chatter—it's a high-stakes convergence of policymakers, financial institutions, fintech innovators like EFICYENT, and the money folk looking to mold the future of...

Retirement Dreams Dashed: 61% Withdraw Early

By Olivia Taylor Updated Nov 14, 2026 Category News Views 309

Retirement Caught in the Crosshairs Just when you think the path to retirement might clear up, life slaps down older workers with economic reality. A recent LiveCareer survey underscores this financial mess, revealing that 61% of those 50 and older are raiding their own retirement funds to make ends meet. It's enough to make one's head spin. Inflation: The Unwanted Guest...

EZaccessMD Data Breach: Class Action Lawsuit Looms

Data breaches are the bogeyman no one wants lurking in the shadows, and when it’s your personal info at stake, folks rightfully squirm. This recent fiasco at EZaccessMD is one of those unsettling incidents. The word on the street isn't pretty: sensitive medical data has slipped through the cracks, leaving Edelson Lechtzin LLP, a heavyweight in class action maneuvers, to...

WeaveGrid Powers EVConnectNC: Charging Incentives Launched

Transforming Utilities with EVConnectNC In a fresh move by WeaveGrid, North Carolina's Electric Cooperatives have teamed up to roll out EVConnectNC. This innovative program aims to manage the burgeoning demand for electric vehicle (EV) charging in rural and suburban areas under North Carolina's cooperative umbrella. Think of it as a smart way to handle new loads without...

Servier's Data on Tovorafenib Shows Promise in pLGG

New Light on a Critical Challenge Talk about a fight in the dark. Pediatric low-grade glioma (pLGG) is a menace that families dread, an uphill battle with odds that feel relentless. Enter Servier and its four-year updated data on OJEMDA® (tovorafenib), a beacon of hope for kids battling these tricky brain tumors. Results, presented at the SNO meeting, are fresh off the...

Lilly's Obesity Breakthroughs: A Step Beyond the Scale

Pushing the Boundaries of Obesity Treatment Alright, let's cut through the noise and get to what really matters here. Eli Lilly is taking on obesity treatment like it's Clash of the Titans at this year's ObesityWeek 2026 in Washington, D.C. Forget just dropping pounds—Lilly wants to reshape how we think about obesity entirely. They're not just leaning into the scale,...